INTRODUCTION {#sec1-1}
============

*Blastocystis* presents a great challenge to biologists seeking to describe its taxonomy and for parasitologists and clinicians who have struggled for many decades to determine whether it is truly an enteropathogen.\[[@ref1]\] Despite being one of the most common human intestinal protozoans in the developing countries, current knowledge about this parasite is incomplete and contradictory. Several issues are still unresolved and much debated regarding this parasite such as the clinical relevance, pathogenicity and the need for treatment.\[[@ref2]\] In 1916, a study described blastocystosis as "an infection that is difficult to get rid of" although treatment has been available and used for several decades.\[[@ref3][@ref4]\] Patients infected with *Blastocystis* frequently present with gastrointestinal complaints and are treated with the intention to eradicate the parasite. However, an accumulating body of data on treatment modalities indicates that successful antimicrobial eradication of *Blastocystis* is far from straight forward.\[[@ref5]\] In a study from Taiwan on 100 patients who had *Blastocystis* in the feces, all patients improved without specific treatment for *Blastocystis*. Further, on stool examination within 1 year of follow-up, the parasite was undetectable in 91.2% of patients despite their having no specific antiprotozoal treatment.\[[@ref6]\] Little is known about the organism\'s metabolic processes, and conclusive animal models are lacking for cause- and-effect relationship.\[[@ref3]\] As a result of this uncertainty surrounding its pathogenic role, large scale treatment trials are also lacking. Treatment of symptomatic patients is often warranted despite the self-limiting nature of the infection.\[[@ref7]\] Recent data also suggest that *Blastocystis* causes symptoms frequently. Therefore, therapy should be limited to patients with persistent symptoms subsequent to a complete work up for alternative etiologies.\[[@ref8]\] Further, studies reporting therapeutic improvement concomitant with parasite clearance in symptomatic patients substantiates the pathogenic role of the organism and hence, the need for treatment.\[[@ref9]\]

This review provides a comprehensive overview of antimicrobials used to target *Blastocystis* and discusses issues pertaining to drug resistance, treatment failure, re-infection and the current views on treatment modalities.

THERAPEUTIC OPTIONS {#sec1-2}
===================

To date a number of antimicrobial agents have been used to treat *Blastocystis* infection. This includes metronidazole, nitazoxanide, trimethoprim-sulfamethoxazole (TMP-SMX), paramomycin, iodoquinol, ketoconazole, secnidazole, emetine, tinidazole, and the probiotic *Saccharomyces boulardii*. [Table 1](#T1){ref-type="table"} depicts the common drugs used and the treatment regimens.\[[@ref10]\]
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Drugs and dosage schedules for treatment of *B. hominis*
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In instances where treatment is warranted, metronidazole is the most frequently prescribed antibiotic.\[[@ref9]\] With metronidazole, a high proportion of patients achieve clinical remission (88%) and a 6 month fecal clearance (80%).\[[@ref11]\] Though considered for first line treatment, the success of eradicating the parasite with this drug has been reported to be anywhere between 0% and 100%.\[[@ref5][@ref10]\] Metronidazole is prescribed in various dosage regimens ranging from 250 mg to 750 mg 3 times a day for 10 days, to 1.5 g/day for 10 days. It has been used alone or in combination with other drugs such as paramomycin or cotrimoxazole.\[[@ref9]\] There is extensive variation in treatment response to metronidazole.\[[@ref12]\] Accurate prediction of a response is difficult in individual patients.\[[@ref1]\] In a placebo controlled treatment trial of *Blastocystis* infection with metronidazole administered at a dosage of 1.5 g/day for 10 consecutive days, it was observed that diarrhea improved, and there was parasitic clearance from the stools at 1 month following therapy. However, an extension of follow-up at 6 months resulted in an elevated occurrence of parasitological relapses in the metronidazole treated group, both symptomatic, and asymptomatic. Therefore, it is suggested that metronidazole may be ineffective in achieving complete eradication possibly due to resistance. Surprisingly, in the placebo treated group there was a sporadic spontaneous clearance of the parasite from stools and this was more evident at 6 months evaluation.\[[@ref7]\]

In all placebo controlled studies, successful treatment is indicated by the resolution of symptoms in association with the partial or complete eradication of the organisms. However, with metronidazole, microbiological resolution is found only in 80% of treated patients.\[[@ref7][@ref10]\] There are many reasons attributed to this. Treatment confers an enhancement in the reproductive potential of the parasite and thus, the treated parasite reverts to becoming granular with the release of reproductive granules that account for the increased number of parasites in microscopy and cultures encountered sometimes in the post treatment phase.\[[@ref13]\] The cysts forms in addition to being genetically heterogeneous are resistant to the cytotoxic effect of the drug.\[[@ref9][@ref14]\]

Resistance to metronidazole was first reported as early as 1991, thus, undermining its value as a first line treatment.\[[@ref3][@ref13]\] It has been noted that this drug is effective for certain patients but does not provide complete eradication for others, particularly those with severe infection. This variation in treatment response suggests the existence of resistant subtypes of the parasite. Currently no *in vitro* and *in vivo* data unequivocally supports this.\[[@ref12]\] The unresponsive patients are perhaps infected with the resistant subtypes.\[[@ref10][@ref13]\] In a study by Constantine Vassalos *et al*., it was concluded that *Blastocystis* species subtype 3 is the most predominant and intra subtype differences in subtype 3 morphotype exists in relation to their pathogenic potential. Transition from vacuolar to amoeboid form reflects the progression from an asymptomatic to symptomatic state. Hence, searching for amoeboid forms may be helpful before antiprotozoal treatment is attempted.\[[@ref15]\] It is also possible that the apparent failure of treatment is due to patient non-compliance, differing pharmacokinetic properties of drugs and inactivation of the drug by the normal bacterial flora.\[[@ref13][@ref16]\] Recent studies have indicated that the human isolates of *Blastocystis* from different geographical locations possess varying degrees of resistance to metronidazole. This implies that an efficient drug or drug combinations at a proper dosage must be instituted in order to eliminate the parasite.\[[@ref3][@ref13]\] One clinic has reported successful treatment with a combination of secnidazole, nitazoxanide, and furazolidone. However, it is to be noted that all three drugs are not currently available in many countries.\[[@ref3]\] A 2006 text described an USA patient returning from Nepal with chronic Blastocystosis who was treated without success over a period of 3 years with iodoquinol, paramomycin, doxycycline, albendazole, tinidazole, ornidazole, quinacrine, nitazoxanide, rifaximin, furazolidone, cotrimoxazole, itraconazole, ketoconazole, and various combinations of these drugs.\[[@ref17]\] One recent study on metronidazole resistance and subtype dependent variation in drug susceptibilities of *Blastocystis* revealed that subtype 7 and subtype 4 are resistant to metronidazole and also exhibit cross resistance to tinidazole, indicating that new unknown mechanisms of activation and/or resistance may be involved.\[[@ref12]\] Nasirudeen *et al*., reported that metronidazole induces programed cell death in *Blastocystis* and apoptosis like features are observable in growing axenic cultures. The central vacuole of *Blastocystis* acts as a repository where apoptotic bodies are stored before being released into the extracellular space. Little is known about the organism\'s metabolic processes, although one study has identified the role of mitochondrion like organelles in the reduction of ferrodoxins in subtype 7 that plays a role in the conversion of metronidazole into its active state.\[[@ref18][@ref19][@ref20]\]

Association between *Blastocystis* and irritable bowel syndrome (IBS) has been suggested in the recent literature. One study on IBS patients, revealed 60% resistance to 0.1 mg/ml of metronidazole while another Indonesian study observed resistance at 1.0 mg/ml metronidazole.\[[@ref9][@ref13][@ref21]\] In at least 10% of IBS patients, *Blastocystis* cannot be successfully treated. This can be either due to resistance or defective clearance secondary to decreased humoral and cellular immune functions.\[[@ref22]\]

TMP-SMX has been shown to have good effects on the cure rate and the clinical symptoms in patients with *Blastocystis* infection. It is considered to be superior to metronidazole in the treatment without the side-effects.\[[@ref23]\] This drug is suggested as an alternative particularly if symptoms persist after treatment with metronidazole.\[[@ref24]\] TMP-SMX is safe to use in pregnant women and is cheaper in terms of cost.\[[@ref23]\] Whether the drug has a direct effect on the parasite itself or kills the essential intestinal bacteria for the survival of *Blastocystis* is not clear.\[[@ref23]\] In a study carried out in Turkey by Ok *et al*., it was demonstrated that patients treated with TMP-SMX experienced 100% recovery.\[[@ref25]\] In another study, treatment with TMP-SMX for 7 days, only 97.3% of cases showed clinical improvement.\[[@ref26]\] More recently, it has been opined that there is no advantage of TMP-SMX over placebo in the treatment of recurrent abdominal pain caused by *Blastocyst*isin children. The eradication rate in children is 35% compared to 44% with metronidazole as second line treatment. It is assumed that TMP/SMX leads only to a reduction in the number of *Blastocystis* and not to permanent eradication.\[[@ref27]\] Research on subtype dependent variation in susceptibility revealed higher susceptibility of *Blastocystis* to TMP-SMX ratio of 1:2 than to a ratio of 1:5. At this ratio, it was observed that there is no subtype dependent variation in susceptibility and 95-100% of cases achieved eradication\[[@ref12]\] In contrast Moghaddam *et al*., reported only 22% eradication of the parasite on treatment with TMP-SMX.\[[@ref28]\] In Human immunodeficiency virus infected patients the prophylactic use of TMP-SMX leads to a decreased detection rate of *Blastocystis*.\[[@ref29]\]

Nitazoxanide, a 5-nitro thiazole, broad spectrum antiparasitic agent is found to have potent activity against *Blastocystis*.\[[@ref10][@ref30]\] In children, the achievable clearance rates are 97-100% on treatment with this drug. It is well-tolerated with no serious adverse effects.\[[@ref30]\] Metronidazole treatment failures in *Blastocystis* may well respond to nitazoxanide.\[[@ref12]\] *In vitro*, *Blastocystis* subtype 7 has been found to be significantly more susceptible to nitazoxanide than subtype 4, though both are considered to be nonhuman subtypes. A placebo controlled trial of nitazoxanide 500 mg twice daily for 3 days reported a clinical and parasitological cure of 86%.\[[@ref31]\] Paramomycin, a broad spectrum aminoglycoside antibiotic was useful to successfully treat *Blastocystis* associated cutaneous lesions particularly urticaria.\[[@ref32]\] In some studies, it has exhibited superior performance in comparison to metronidazole. With an eradication rate of 77%, treatment with paramomycin appears significantly more effective than treatment with metronidazole (38%) or no treatment (22%).\[[@ref2]\] Treatment failure was suspected in one out of three patients in a study, and this patient was subsequently successfully treated with metronidazole.\[[@ref9][@ref33]\] Curiously, an early *in vitro* study revealed that paramomycin was not inhibitory to the parasite. Since, it is bactericidal it might act by the destruction of the gut bacterial flora essential for *Blastocystis* survival.\[[@ref9]\] Mirza *et al*., have reported that paramomycin has no activity against the nonhuman subtypes of *Blastocystis*.\[[@ref12]\]

Other drugs that are found to have variable efficacy on *Blastocystis* are tinidazole, ornidazole, secnidazole, ketoconazole, pentamidine, furazolidone, quinine, iodoquinol, iodochlorhydroxyquin, and emetine.\[[@ref10][@ref12]\] The activity of emetine against *Blastocystis* has been evaluated in 3 previous *in vitro* studies. While two studies reported its effectiveness, Zierdt *et al*., reported strain-to-strain variation in the susceptibility of the parasite to the drug.\[[@ref34]\] It has also been observed that emetine resistance occurs along with metronidazole resistance thereby suggesting that multidrug resistant phenotypes might be present in the parasite. Clinically, however, emetine has limited use because of its severe side effects. *Blastocystis* subtype 4 is resistant to emetine and variably susceptible to quinacrine and mefloquine. Furazolidone is another drug with anti *Blastocystis* activity and to date no subtype dependent variation has been observed for this drug.\[[@ref12]\]

Cysteine proteases play an important role in the cell cycle and pathophysiology of *Blastocystis* and induce up regulation of pro-inflammatory cytokines. This finding suggests a potential role for cysteine proteases inhibitors as a therapeutic option for *Blastocystis* isolates resistant to conventional agents.\[[@ref12][@ref35]\]

*S. boulardii* is a non-pathogenic yeast and has proven effective in gastrointestinal diseases with predominant inflammatory component, indicating its role in interference with cellular signaling pathways and it is marketed as a dietary supplement. It regulates the intestinal microbial homeostasis, interferes with the ability of pathogens to colonize and infect the mucosa, modulates local and systemic immune responses, stabilizes gastrointestinal barrier functions and induces enzymatic activity favoring absorption and nutrition.\[[@ref36]\] In a randomized single blinded clinical trial in symptomatic children who had *Blastocystis* positive stools, both clinical and parasitological cure rates were 94.4% in comparison with 73.3% achieved in the metronidazole treated group. These findings challenge the existing guidelines for treatment.\[[@ref8]\]

A few traditional Chinese medicinal herbs have also been examined for *in vitro* activity against *Blastocystis* (*Brucea javanica* and *Coptis chinensis*). Their inhibitory activity was not as great as with similar concentrations of metronidazole. As an adjunct, dietary management strategies like introduction of high fiber and lactose free diet is shown to improve clinical signs and symptoms.\[[@ref24]\]

There have been several studies examining the use of alternative agents for the treatment of *Blastocystis* infection. *Blastocystis* isolates from IBS patients mostly genotype-1 have demonstrated increased susceptibility to garlic at 0.01 mg/ml. Other investigational agents such as ginger, black pepper, and white cumin did not have significant inhibitory effect in drug susceptibility assays.\[[@ref37]\]

In summary, a variety of drug treatment options are available for *Blastocystis* infections \[[Table 1](#T1){ref-type="table"}\]. Metronidazole appears to be the most effective drug for *Blastocystis* chemotherapy despite some evidence for treatment failure. In such circumstances, TMP-SMX and nitazoxanide may be considered as second choice drugs. Treatment should be instituted if the diarrhea is persistent and no other causative pathogen is identified in fecal specimens. Future studies should investigate the association between genotypes and variations in drug susceptibility. The mechanisms of action and the mode of resistance to each of the drug has to be evaluated further.\[[@ref9]\] Genome analysis of the species and application of modern techniques, such as microsatellites, microarrays and differential display coupled with proteonomics and bioinformatics analysis are more likely to elucidate the differences in pathogenicity, virulence and response to treatment.\[[@ref15]\] The development of new therapeutic options to counter antimicrobial resistance requires the use of high through put screening tools.\[[@ref12]\]
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